I like PFE, the Allergan merger lowers their tax rate by 8% due to the inversion, also with AGN projected FY 2018 earnings @ 21.00 share that's a forward PE of 17 based on the 363.63 takeover price, and the 3.5% div yield ain't bad either. Also Bought OPK, based on recent takeover of Bio Reference Labs and the CEO has been buying like crazy.
Last edited by Baychamp1; 11-25-2015 at 09:38 AM.
|